Founder & CEO · Strand Therapeutics · Cambridge, Massachusetts, United States
Fresh capital means vendor and tool decisions are happening right now.
Open roles signal budget is being allocated across the org.
Most founders lock in key vendors within 60 days of closing a round.
Clinical-stage biotech developing breakthrough mRNA therapeutics with targeted delivery systems for solid tumors, autoimmune diseases, and blood cancers.
